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Acute intracerebral haemorrhage:
diagnosis and management
Iain J McGurgan ,1 Wendy C Ziai,2 David J Werring,3 Rustam Al-
Shahi Salman,4 Adrian R Parry-Jones5
ABSTRACT
Intracerebral haemorrhage (ICH) accounts for half
of the disability-adjusted life years lost due to
stroke worldwide. Care pathways for acute stroke
result in the rapid identification of ICH, but its
acute management can prove challenging
because no individual treatment has been shown
definitively to improve its outcome. Nonetheless,
acute stroke unit care improves outcome after
ICH, patients benefit from interventions to
prevent complications, acute blood pressure
lowering appears safe and might have a modest
benefit, and implementing a bundle of high-
quality acute care is associated with a greater
chance of survival. In this article, we address the
important questions that neurologists face in the
diagnosis and acute management of ICH, and
focus on the supporting evidence and practical
delivery for the main acute interventions.
INTRODUCTION
Spontaneous intracerebral haemorrhage
(ICH) refers to non-traumatic bleeding
in the brain parenchyma and is the
deadliest form of stroke. The high
1-month case-fatality rate of ~40%
and poor long-term outcome make it
a major contributor to global morbidity
and mortality.1 2 Although ICH
accounts for a minority of stroke world-
wide (10–30%), it is associated with
a greater burden of disability-adjusted
life years than ischaemic stroke, given
its high incidence in low- and middle-
income countries.3 Despite dramatic
drops in ischaemic stroke mortality
rates,3 there has been limited improve-
ment in case fatality from ICH in the
last few decades2 4 5 and most survivors
are left with severe disability.2 6 7
ICH is not a single entity; 85% of cases
are due to cerebral small vessel disease,
predominantly deep perforator arterio-
pathy (also termed hypertensive arterio-
pathy or arteriosclerosis) and cerebral
amyloid angiopathy, while the remainder
results from a macrovascular (eg, arterio-
venous malformation, cavernoma, aneur-
ysm and venous thrombosis) or
neoplastic cause. Vascular malformations
are the most common cause of ICH in
young adults, accounting for up to one-
third of cases.8 The term ‘primary’ ICH is
often applied to cases caused by cerebral
small vessel disease, but it discourages
adequate investigation and accurate clas-
sification and is not recommended. Deep
haemorrhages account for about two-
thirds of cases, occur in the internal cap-
sule, basal ganglia or brainstem, andmore
likely result from deep perforator arter-
iopathy. About 5–10% of ICH occurs in
the cerebellum. The remainder is lobar
haemorrhage located in cortico-
subcortical areas, often near or reaching
the cerebral convexities, of which ~40%
are due to arteriosclerosis alone, ~40%
to arteriosclerosis and amyloid angiopa-
thy and the remaining ~20% to amyloid
angiopathy alone.9
There are no medical treatments for
acute ICH that have been definitively pro-
ven in primary outcome analyses of ran-
domised clinical trials. Patients with ICH
are frequently referred for surgery, but the
roles of various surgical methods and tim-
ing of surgery remain controversial. In this
article, we outline a practical approach to
the diagnosis and management of
acute ICH.
ACUTE EVALUATION
Time is limited;what information do I need to
obtain early on?
The approach to an efficient and focused
history and physical examination in sus-
pected acute stroke has been outlined in
the first article in this series.10 It is impor-
tant to obtain a history of any recent
trauma, including from a witness if avail-
able, and to assess for any circumstantial
evidence, making sure to determine
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clinically whether the trauma preceded the haemor-
rhage or vice versa. Acute ischaemic stroke and ICH
cannot be reliably distinguished at the bedside but the
diagnosis is made rapidly and easily on imaging, so
every effort should be made to minimise delays to the
initial CT brain scan. Crucial information specific to
the management of ICH must be obtained as early as
possible after the CT brain scan; table 1 lists the key
questions to ask focused on modifiable predictors of
outcome.
The National Institutes of Health Stroke Scale
(NIHSS) used for ischaemic stroke is also valuable in
ICH, but its utility may be limited by the more frequent
occurrence of depressed consciousness in ICH.21 The
Glasgow Coma Scale (GCS) score is the most useful
initial evaluation because of its similar prognostic value
to NIHSS, its simplicity and its incorporation in the
ICH score (figure 1 outlines its calculation). However,
as in ischaemic stroke, aphasia can reduce the verbal
subdomain score, and thus cause underestimation of
the GCS.
What baseline tests should I perform?
For all the complexity and uncertainty in ICHmanage-
ment, the initial diagnosis of acute blood in the brain
substance is straightforward. Non-contrast brain CT
(figure 2) is rapid, highly sensitive and specific for all
forms of ICH, andwidely available, so is considered the
reference standard for ICH diagnosis.21 26 27
The CT scan should be assessed for ICH location,
brain changes consistent with small vessel disease (atro-
phy, leukoaraiosis (figure 2) and lacunes), the presence
and degree of mass effect or midline shift, hydrocepha-
lus, intraventricular extension and the size of the hae-
matoma. Haematoma volume independently predicts
haematoma expansion and early mortality11 28 and can
be estimated rapidly and accurately on CT with the
ABC/2 formula, as shown in figure 1. A blood-fluid
level is highly specific for coagulopathy or the use of
anticoagulants and should prompt a search for these
factors if not already established.29MR is as sensitive as
CT in the hyperacute diagnosis of ICH26 30 but it rarely
provides more information in the acute stage; the
longer scan duration and delays obtaining MR for
often critically ill patients make CTa preferred choice.
Blood tests including coagulation studies, glucose,
cardiac-specific troponin and a toxicology screen
should be performed. Point-of-care INR testing should
be implemented to avoid delays in anticoagulation
reversal for patients taking warfarin.31 ECG abnorm-
alities are common, but concomitant myocardial injury
should not be overlooked.32
Do I need to request further imaging?
Early diagnosis of macrovascular causes of ICH allows
timely starting of specific treatment and refines the
prognosis. The decision whether to pursue further ima-
ging has often been made based on assumptions guided
Table 1 Important information to obtain as soon as possible after ICH to guide prognostication and management
Question to ask Rationale
Is the patient taking anticoagulation or antiplatelet
medications?
Anticoagulant and antiplatelet use are independent predictors of haematoma
expansion11 and death.12
Further details of antithrombotic treatment: what agent,
what dose and when was the most recent dose (or the
most recent International Normalised Ratio(INR) for
warfarin)?
This is relevant to establish if anticoagulation reversal is needed, and if so, the type and
dose of reversal agent to be used.
What was the time of onset of symptoms? This is obviously crucial to determine in all stroke presentations, but is relevant in ICH as
the time from symptom onset to baseline imaging relates inversely to the risk of
haematoma expansion11 and determines whether to pursue acute blood pressure
lowering. Most expansion occurs in the first few hours after ICH.13 It is also important to
establish whether the imaging appearances are consistent with the time of onset;
a haematoma may appear isodense with brain tissue as early as five days after the
onset, so the diagnosis may be missed if CT imaging is delayed.
Is the patient’s blood pressure elevated (systolic blood
pressure >150 mm Hg)?
Blood pressure is frequently very high in the acute phase.14 Elevated systolic blood
pressure is associated with further neurological deterioration and mortality15 16 and
early treatment may be beneficial, although there is much uncertainty about this.
Has ICH been distinguished from haemorrhagic
transformation of ischaemic stroke?
ICH cannot always be definitely distinguished from haemorrhagic transformation of
infarction on imaging.17 Features suggesting haemorrhagic transformation include
a patchy rather than uniform appearance of the haematoma, hypodensity surrounding
the haematoma that may reach the cortex in a wedge shape, and evidence of an
occluded vessel visible in the same arterial territory.
Are there imaging or clinical signs of intraventricular
extension of haemorrhage and hydrocephalus?
Intraventricular extension of haemorrhage and raised intracranial pressure (ICP) from
hydrocephalus each predict higher mortality and poor functional outcome18 and require
urgent consideration for surgical management (external ventricular drain insertion).
Are there imaging or clinical signs of mass effect and
increased ICP?
Blood pressure targets may require revision if there are signs of elevated ICP, and
hyperosmolar agents and ICP management may be indicated.19 20
ICH, intracerebral haemorrhage.
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by patient risk factors, but these are not a reliable way
to exclude a potential macrovascular cause in all cases,
and clinical practice varies widely.33
CTangiography (CTA) should be performed acutely in
all patients, preferably within 2 days of the non-contrast
brain CT,34 except those definitely at low risk of having
an underlying macrovascular cause (figure 3). Imaging
predictors of haematoma expansion on CTA such as the
‘spot sign’ (foci of contrast extravasation within the
haematoma) may also add prognostic value.11 35 If
CTA is negative for structural vascular abnormalities,
MR/MR angiography should be considered as soon as
possible as it has additional diagnostic yield.34 Digital
subtraction angiography is then warranted in patients at
high risk of an underlying macrovascular cause after
negative CTA (and negative MR, if performed).34
There is an appreciable yield of repeat digital subtraction
angiography performed a few weeks later, especially in
lobar ICH,36 so persistence is often required.
Beyond the acute phase, MR (including blood-
sensitive sequences to detect cerebral microbleeds and
cortical superficial siderosis) provides important addi-
tional information about the underlying cerebral small
vessel disease.
Figure 1 Upper panel: Calculation of the intracerebral haemorrhage score, a clinical grading scale and a useful communication tool.
Predicted 30-day case-fatality rates are derived from the original validation study22; *a subsequent study in which early do-not-
resuscitate orders were not placed observed 30% lower mortality rates.23 Lower panel: The use of the ABC/2 calculation (essentially the
formula for the volume of an ellipsoid) to rapidly and accurately24 25 estimate the volume of an acute left-sided ganglio-capsular
haemorrhage on non-contrast CT brain scan. (Copyright Iain McGurgan).
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Should I pursue intensive treatment?
The focus for the great majority of patients should be on
the full provision of high-quality active treatment and
supportive care, at least in the first 24–48 hours.
Decisions about instituting a ceiling of care should
dependonan assessment of prognosis, but this is difficult
to determine acutely. There are multiple dedicated ICH
prognostic grading scales, themostwidely used being the
ICH score,22 which has acceptable discrimination for
functional outcome measured by the modified Rankin
score at up to 12 months (figure 1). Such scales should
not be used, however, as the sole means to gauge prog-
nosis or guide the withdrawal of supportive treatment.21
Like other conditions with high rates of poor out-
comes and a perceived lack of effective treatments,
ICH is vulnerable to therapeutic nihilism. Early ceilings
of care and a focus on comfort measures are more likely
to be pursued acutely in ICH than in ischaemic stroke,
independent of neurological deterioration and co-
morbidities, and are associated with poorer outcome.41
While timely do-not-resuscitate orders are important
considerations in stroke management, these should not
influence other aspects of care. In practice, however, do-
not-resuscitate orders in ICH often herald less active
supportive care,42 43 so clinicians should be cautious
when considering early do-not-resuscitate orders.
ACUTE MANAGEMENT
How do I approach the management of ICH?
ICH is a neurological emergency. The presence of
expanding haematoma and vasogenic oedema inside
the fixed volume of the cranial vault can lead to
a precipitous increase in intracranial pressure (ICP)
and fatal brain herniation syndromes. The principle of
‘time is brain’ also firmly applies to ICH; haematoma
expansion occurs very early11 and independently pre-
dicts a poor outcome.18 The rapid delivery of a care
bundle incorporating anticoagulation reversal, inten-
sive blood pressure management and neurosurgery/cri-
tical care if required has been associated with
a substantial improvement in 30-day case-fatality
rates.44
The overarching goals of acute management are to
stabilise the patient to ensure they survive the initial
insult, and to prevent secondary brain injury (figure 4).
Patients with ICH may require immediate intensive
care unit admission. Otherwise, all patients should be
admitted to an acute stroke unit as soon as possible; the
benefit is at least as great for patients with ICH as it is
for those with ischaemic stroke.45 The general princi-
ples of acute care are the same as those for acute
ischaemic stroke, as outlined in the first article in this
series.10 Secondary prevention measures, cerebral
small vessel disease and decisions regarding restarting
antithrombotic therapy will be addressed in subsequent
articles.
Management of the complications of ICH is a key
focus of acute care. Raised ICP can result from themass
effect of the bleed or peri-haematomal oedema or from
hydrocephalus. Although there is a lack of evidence to
guide its management in ICH, measures used for raised
ICP in other settings may help. These include raising
the head of the bed to 30° (althoughwithout supportive
evidence in acute stroke46), mild sedation, analgesia
and mannitol (or hypertonic saline, depending on car-
diac and renal comorbidities).18 Intensive ICPmonitor-
ing is recommended in those with a GCS<9, evidence
of herniation or hydrocephalus.21 Corticosteroids are
possibly associated with more harm than benefit when
used for lowering ICP in ICH, so should not be used.47
Early-onset seizures are not uncommon, occurring in
one in seven patients, with most occurring at or near
the onset.48 Clinical seizures should be managed with
antiseizure medications, but prophylactic treatment
should not be offered routinely.21 Cortical involve-
ment, age younger than 65 years, volume greater than
10mL and early seizures within 7 days of ICH identify
patients at higher risk of subsequent late seizure
development.49
If the patient takes anticoagulant treatment, how do
I reverse it?
Anticoagulation-associated ICH accounts for nearly
20% of all cases.50 The haemorrhage in this setting is
of larger volume,51 52 is more likely to exhibit
Figure 2 This axial non-contrast CT brain scan shows an acute
large right parietal lobar haematoma, with moderately severe
confluent low attenuation (leukoaraiosis) extending from the
lateral ventricles into the subcortical white matter. (Copyright
David Werring.)
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haematoma expansion11 and is associated with higher
morbidity and mortality53–55 compared with ICH not
associated with anticoagulation. Stopping antithrombo-
tic therapy and reversing anticoagulation immediately
after the diagnosis of ICH is, therefore, crucial.56
Although ICH risk associated with the use of direct
oral anticoagulants (DOACs) was around half that of
warfarin in randomised trials,57 a previous lack of spe-
cific reversal agents for DOACs prompted concerns that
DOAC-associated ICH may be associated with poorer
outcomes. In fact, the prognosis of ICH associated with
DOACs is likely better58 or at least no worse59 than that
of warfarin, and the availability of approved specific
reversal agents for DOACs has improved. Table 2 pro-
vides a guide to the reversal of anticoagulation.
Poorer outcomes are also seen for ICH associated
with antiplatelet therapy,70 but platelet transfusions
increase rather than decrease morbidity and mortality
in this group,71 and therefore should not be used.
Patients with ICH in the context of coagulation fac-
tor deficiencies or thrombocytopaenia should undergo
replacement, with input from a haematologist.21
Several trials have assessed the efficacy of coagulation
factors more generally in the management of acute ICH
but found that the risk of thromboembolic compli-
cations outweighed the benefits.72 A trial of early
administration of factor VIIa in an identified sub-
group of patients most likely to benefit, however,
has been approved (FASTEST, NCT03496883).
Antifibrinolytic drugs, on the other hand, have
Figure 3 Algorithm with risk stratification to aid decision-making on further imaging, and the diagnostic yield of intra-arterial digital
subtraction angiography in ICH. CTA, CT angiography; DSA, digital subtraction angiography; ICH, intracerebral haemorrhage. ¥Parameters
for pre-test risk estimation are derived from scoring systems based on patient characteristics and non-contrast CT from the DIagnostic
AngioGRAphy to find vascular Malformations (DIAGRAM) study, a prospective, multicentre study assessing the accuracy of multiple
imagingmodalities in the diagnosis ofmacrovascular causes of ICH.34 37 Individualsmeeting the ‘low risk’ criteria abovewere excluded from
the DIAGRAM study because of the low probability of finding an underlying macrovascular cause,38 and the yield of CTA in the remainder
was 17%. Low rates of underlying macrovascular causes in this group were confirmed in a subsequent validation cohort.37 Primary
intraventricular haemorrhage (ie, that with no discernible parenchymal component) has been added to the high-risk group, based on high
detected rates of underlyingmacrovascular causes.39 ¶Acute CTA should be performedwithin 2 days of CT, where possible. The diagnostic
algorithm of the yield of intra-arterial DSA based on the CTA and clinical characteristics has been adapted fromWilson et al.40 MR/MR
angiography performed acutely after a negative CTAmay have additional value, particularly for the diagnosis of non-macrovascular causes,
before considering intra-arterial DSA.34 *Confluent leukoaraiosis (see figure 2) or lacunar infarction on acute CT brain scan.
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proven promising. A large trial of intravenous tra-
nexamic acid (TICH-2) showed a significant reduc-
tion in haematoma growth and early mortality, but
there was no overall benefit for the primary out-
come of later functional recovery,73 and it is thus
not recommended as part of current care. A further
study focusing on effects on early mortality and
targeting earlier treatment is planned, and an
ongoing trial is evaluating tranexamic acid in hyper-
acute presentations of ICH including mobile units
(STOP-MSU, NCT03385928). Randomised evi-
dence on associations of tranexamic acid in antic-
oagulation-associated ICH is lacking, although
a trial in DOAC-associated ICH is currently under-
way (TICH-NOAC, NCT02866838).
Do I need to lower the patient’s blood pressure, and if so,
by how much?
Observational data suggest that blood pressure is very
high in the acute phase after ICH, significantly higher
than that after ischaemic stroke.14 High blood pressure
in acute ICH is associated with haematoma expansion
andpoor clinical outcome.15 16 There have been concerns
for many years that high blood pressuremay be necessary
to ensure adequate cerebral perfusion after ICH, and that
aggressively treating it may cause harm. Such concerns
have been assuaged by evidence that suggests that
adequate cerebral blood flow is maintained after
acute blood pressure reduction in ICH.74 75
However, results of the two largest trials of intensive
blood pressure lowering early after ICH76 77 have
Figure 4 Schema of the time course and mechanisms of secondary brain injury in intracerebral haemorrhage, including intraventricular
haemorrhage.
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renewed uncertainty. Meta-analyses of these trials and
other smaller studies showed that early intensive blood
pressure lowering was safe, but without functional or
mortality benefit.78–82 In contrast, a linear association
between systolic blood pressure achieved in the first
24 hours and functional status was found in a recent
individual participant data meta-analysis of the two lar-
gest trials, with improvements in functional recovery
seen for blood pressure as low as 120–130 mm Hg.83
These trials excluded patients with large and severe
haematomas, however, so caution must be exercised
when treating such patients, especially where large
reductions in very hypertensive patients might predis-
pose to harm.19 84 Table 3 provides some practical
advice for blood pressure management in acute ICH,
based on existing guidelines.85 It should be noted that,
in light of the uncertainty described above, future
research might conclude that there is no benefit from
acute intensive blood pressure lowering.
Which patients should I refer for neurosurgery?
The rationale for clot removal surgery is to reduce
direct and secondary brain injury (figure 4). The
location of ICH has a large bearing on decision-
making. Neurosurgical intervention is generally recom-
mended for infratentorial bleeding despite a lack of
randomised evidence,88 given the high risk of brain-
stem compression and herniation syndromes in the
confined space of the posterior fossa. Clinical guide-
lines recommend posterior fossa decompressive eva-
cuation for cerebellar ICH>3 cm in diameter, or for
smaller haematomas associated with brainstem com-
pression or hydrocephalus from ventricular
obstruction.21 This recommendation is based on obser-
vational evidence that haematoma evacuation is asso-
ciated with decreased mortality, but there is no
evidence for improvements in functional outcome.89
Management of hydrocephalus by external ventricular
drainage alone is not recommended in this setting and
may be harmful, especially if the basal cisterns are
compressed.90 The lack of clinical equipoise probably
precludes the design of any future randomised trials to
address the question of surgical vs conservative
management.
Equipoise exists in bounds, however, where supra-
tentorial haemorrhage is concerned. Seventeen
Table 2 Strategies and rationale for anticoagulation reversal in acute ICH
Anticoagulant Reversal strategy Rationale
Warfarin (1) Stop warfarin immediately and check the INR, but don’t
wait for the result to act in life-threatening bleeds.60 61
(2) Vitamin K 10 mg intravenous infusion (slow-acting),
monitor for anaphylaxis.
(3) Four-factor prothrombin complex concentrate with
INR-based dosing.
(4) Repeat INR every 3–6 hours; the optimal target is
uncertain, but aim for normalisation of the INR (<1.3).
Prothrombin complex concentrate is superior to fresh
frozen plasma in normalising the INR for warfarin-
associated ICH.62 Vitamin K administration, in addition,
may help to prevent a later re-increase in INR.63
Dabigatran (1) Stop dabigatran immediately, check thrombin time,
activated partial thromboplastin time.
(2) Consider oral-activated charcoal (50 g) if last intake is
<4 hours and safe to administer to the patient.
(3) Idarucizumab 2×2.5 g boluses intravenously if recent
ingestion or prolonged laboratory clotting times (not
recommended if the thrombin time is within the normal
range).
Idarucizumab, a humanised monoclonal antibody
fragment, rapidly and safely reverses dabigatran
anticoagulation.64 Effects on haematoma expansion are
uncertain, as follow-up imaging was not mandated in
the trial.
Factor Xa inhibitors
(apixaban, rivaroxaban,
edoxaban and betrixaban)
(1) Stop the agent immediately, check prothrombin time,
anti-factor Xa activity.
(2) Consider oral-activated charcoal (50 g) if last intake is
<4 hours and safe to administer to the patient.
(3) Andexanet alpha intravenous bolus and infusion,
dosing dependent on the dose and last dose timing of the
factor Xa inhibitor.
(4) Most centres have protocols prescribing the use of
andexanet alpha; prothrombin complex concentrate is still
more often used in practice.65
Andexanet alpha, a recombinant inactive factor Xa
‘decoy’, rapidly and effectively reduces anti-factor Xa
activity.66 A trial in ICH is ongoing. Given that clinical
and cost-effectiveness has not yet been confirmed,
a recent National Institute for Health and Care
Excellence (NICE) guideline consultation has not
recommended its use.67
Heparin (1) Stop heparin infusion/low-molecular-weight heparin
(LMWH) immediately, check activated partial
thromboplastin time.
(2) Protamine sulphate slow intravenous infusion, 1 mg
per 100 units of heparin, if activated partial
thromboplastin time is prolonged or heparin was
administered within the previous 2 hours.
(3) Max dose 50 mg, monitor for anaphylaxis.
Protamine sulphate fully reverses the effect of
unfractionated heparin but only partly neutralises the
effect of LMWH; the same dosing strategy can be used,
but the longer half-life of LMWH may require cautious
repeat infusions.68 Further evidence is needed to
establish the role of andexanet alpha in the management
of LMWH-associated ICH; trials are ongoing.69
ICH, intracerebral haemorrhage.
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randomised controlled trials have addressed surgical
evacuation of supratentorial ICH, with all of the larger
trials andmeta-analyses returning neutral results on the
primary outcomes.91 As a result, best medical manage-
ment is usually pursued, but trials were complicated by
high crossover rates, and there appear to be subgroups
of patients who might benefit from surgical interven-
tion. Patients with a GCS at presentation of 10–13, that
is, not at either extreme of arousal, those with large
ICH and those with superficial bleeds may experience
improved outcomes.92–94
Multiple surgical techniques have been investigated
for different indications; table 4 provides a summary
of the evidence for each. Developments in minimally
invasive surgery for patients with supratentorial ICH
are promising. The only large trial of catheter
evacuation followed by irrigation with alteplase
(MISTIE III95) found no clear benefit but noted that
the procedure was safe. There was, however, evidence
of functional improvement in patients meeting the
surgical goal of reducing haematoma size to
<15 mL.96 The ongoing ENRICH trial
(NCT02880878) is investigating a novel minimally
invasive technique involving a small-directed craniot-
omy and image-guided trans-sulcal evacuation97 and
is one of several currently enrolling trials, some with
an earlier time window for surgery (Dutch ICH
Surgery Trial, NCT03608423; MIND,
NCT03342664; INVEST, NCT02654015).
Optimal timing of surgical intervention remains
controversial due to the risk of re-bleeding,
although reducing haematoma volume early may
Table 3 Strategies for blood pressure management in acute ICH based on the most recent UK85 86 and US21 ICH management guidelines. Blood pressure
management strategies in rows 1–3 are relevant to patients presenting within 6 hours of symptom onset
Blood pressure management questions Management strategy (for mild-to-moderate ICH)
What blood pressure warrants acute
treatment?
Reduce blood pressure in people with acute ICH who have a blood pressure of 150–220 mm Hg
with symptom onset within the last 6 hours.
What blood pressure should I target? Aim for a systolic blood pressure of 130–140 mm Hg, sustained thereafter for at least a week.
How rapidly should I lower blood pressure? In most cases, aim to achieve the target blood pressure within 1 hour of starting treatment. Rapid
blood pressure lowering should be avoided if elevated ICP is suspected, the GCS is <6, or
neurosurgical evacuation is pending.
What agents should I use? Local protocols usually exist for guiding the choice of agent. Intravenous treatment (bolus or
infusion) is generally warranted. Glyceryl trinitrate and labetalol are commonly used. Oral (or
nasogastric) treatment should be started as soon as possible for maintenance treatment, and the
intravenous therapy weaned and stopped within 2–3 days.
Should prehospital blood pressure treatment be
advised?
Prehospital treatment with glyceryl trinitrate appeared to worsen outcome in a subgroup analysis
of the RIGHT-2 trial,87 so ultra-acute treatment may be harmful and should not be used.
ICH, intracerebral haemorrhage; ICP, intracranial pressure; GCS, Glasgow Coma Scale.
Table 4 Summary of the evidence for different neurosurgical techniques in ICH
Surgical technique Evidence
Open craniotomy Craniotomy was the selected surgical management for most patients in the largest trials to date.94 98 There was no
benefit from early haematoma evacuation in either, but surgery was performed relatively late, and a marginal
improvement in mortality was shown for those with superficial ICH without intraventricular extension.
Minimally invasive surgery
(±clot lysis)
Minimally invasive surgical techniques incorporate removal of the haematoma in a single procedure using an
endoscope or exoscope, or image-guided placement of a drainage catheter followed by catheter irrigation with
a thrombolytic agent to allow passive drainage of the haematoma over several days. A variation, the minimally
invasive craniopuncture technique, has been standard ICH surgical practice in China and improved independent
survival in small basal ganglia ICH in a randomised trial.99 These techniques hold promise for the surgical
management of deep bleeds, where access is limited or risky for open surgery, and recent meta-analyses
demonstrated higher rates of good functional outcome than after medical management.91 100
External ventricular drainage
(±clot lysis)
Intraventricular extension of haemorrhage occurs in 30–50% of patients with ICH, predisposes to the development
of hydrocephalus and strongly predicts a poor prognosis.18 Insertion of an external ventricular drain to remove
haemorrhage and monitor pressure improves survival.21 Functional outcome was not improved in the CLEAR III
trial of alteplase versus saline irrigation in those with pre-placed drains.101 A low proportion of participants in the
trial achieved complete/near-complete clot removal, however, and functional benefit from removing greater
amounts of haemorrhage volume remains a possibility.
Decompressive craniectomy The aim of decompressive craniectomy is to mitigate the consequences of mass effect, in particular that of delayed
oedema. Safety of the procedure and potential beneficial effects have been shown in retrospective studies and case
series.102–105 The first randomised controlled trial to compare the procedure to best medical treatment (SWITCH,
NCT02258919) is currently underway.
ICH, intracerebral haemorrhage.
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reduce secondary brain injury and could improve
outcome.91 100
FUTURE DIRECTIONS
Themanagement of ICHhas not paralleled the dramatic
advances in acute ischaemic stroke therapeutics driven
by many large randomised controlled trials. Clinical
trials in ICH face unique challenges; a less common
and more severe on average condition with poorly
understood pathophysiology results in a sizeable propor-
tion of patients being ineligible.106 Aspiring to recruit
every ICH survivor to at least one trial is the only way to
resolve uncertainties and improve outcome. Fortunately,
we have much about which to be optimistic. There are
currently over 60 active recruiting (or soon-to-be
recruiting) ICH trials, many focused on the possible
interventions of haemostatic agents and surgical techni-
ques, where much uncertainty persists.
CONCLUSION
ICH has the worst outcomes of all stroke subtypes, but
increased research interest in recent years has led to
significant advances in its diagnosis and management.
The focus of existing treatment is the prevention of
haematoma expansion, and progress in supportive
care, blood pressure control and anticoagulation rever-
sal has been rewarded with improved outcome. The role
of neurosurgery is still unclear but the field is rapidly
evolving, with minimally invasive techniques showing
promise in selected groups, even in the context of neu-
tral trials so far.
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